Nanopath, a point-of-care diagnostics company, has received $4 million in federal grants from the National Institutes of Health (NIH) and the National Science Foundation (NSF). This funding is intended to support the development of Nanopath’s diagnostic platform, which focuses on pelvic and gynecologic infections and diseases. The grants were awarded through the competitive Small Business Innovation Research (SBIR) Program.
The total federal funding comprises a $3 million grant from the NIH and a $1 million grant from the NSF. This brings Nanopath’s total funding to over $15 million. The company raised a $10 million Series A in 2022.
Nanopath’s diagnostic platform is designed to provide molecular diagnostic information at the point of care, allowing for faster and more accurate medical decision-making. This platform is particularly aimed at transforming the way pelvic and gynecologic infections are diagnosed, providing results that are not only rapid but also clinically actionable.
With the new funding, Nanopath plans to enhance its platform by focusing on the development of test consumables and readout instrumentation. The company also aims to conduct analytical and clinical validation of their lead assay, positioning the technology to potentially become the standard of care for characterizing pelvic and gynecologic infections.
“This funding is a tremendous vote of confidence in Nanopath’s ability to transform molecular diagnostics and enable providers to move away from the traditional view of disease-specific diagnostic testing, and towards patient-centric testing,” said Amogha Tadimety, Ph.D., co-founder and CEO of Nanopath. “The outcomes of this grant-funded work could lay the groundwork for a new era of clinically informative diagnostics at any site-of-care, changing the paradigm of women’s healthcare.”
Nanopath has developed advanced prototypes of both its disposable test cartridge and benchtop readout instrument and is actively developing its pipeline of test offerings through clinical collaborations with preeminent hospitals in New England.
“The groundbreaking data, workflows and prototypes developed by our team over the last year formed the foundation of our applications for both grants,” said Alison Burklund, Ph.D., co-founder and CTO of Nanopath. “Nanopath is commercializing a novel technology that has never before been used for molecular diagnostics. Support from NSF, NIH, and the broader scientific community will catalyze our commercial development.”
